newsfilter
← Latest News
PR Newswire·

REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs

REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene...